688065 凯赛生物
已收盘 11-20 15:00:00
资讯
新帖
简况
凯赛生物(688065)11月19日主力资金净卖出400.54万元
证券之星 · 11-20 08:14
凯赛生物(688065)11月19日主力资金净卖出400.54万元
股市必读:凯赛生物新发布《关于2025年员工持股计划首次授予部分第一个锁定期业绩考核指标达成暨锁定期届满的公告》
证券之星 · 11-20
股市必读:凯赛生物新发布《关于2025年员工持股计划首次授予部分第一个锁定期业绩考核指标达成暨锁定期届满的公告》
凯赛生物(688065)披露2025年员工持股计划首次授予部分第一个锁定期届满公告,11月18日股价下跌1.76%
证券之星 · 11-18
凯赛生物(688065)披露2025年员工持股计划首次授予部分第一个锁定期届满公告,11月18日股价下跌1.76%
凯赛生物(688065)11月12日主力资金净卖出534.08万元
证券之星 · 11-13
凯赛生物(688065)11月12日主力资金净卖出534.08万元
股市必读:凯赛生物新发布《上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司2026年第一次临时股东会的法律意见书》
证券之星 · 11-11
股市必读:凯赛生物新发布《上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司2026年第一次临时股东会的法律意见书》
凯赛生物(688065)披露2026年第一次临时股东会决议公告,11月09日股价下跌0.79%
证券之星 · 11-09
凯赛生物(688065)披露2026年第一次临时股东会决议公告,11月09日股价下跌0.79%
凯赛生物(688065)披露2025年员工持股计划预留授予部分非交易过户完成公告,11月04日股价上涨1.48%
证券之星 · 11-04
凯赛生物(688065)披露2025年员工持股计划预留授予部分非交易过户完成公告,11月04日股价上涨1.48%
凯赛生物(688065)2026年三季报简析:营收净利润同比双双增长,公司应收账款体量较大
证券之星 · 11-01
凯赛生物(688065)2026年三季报简析:营收净利润同比双双增长,公司应收账款体量较大
凯赛生物(688065)9月30日股东户数2.06万户,较上期增加7.55%
证券之星 · 10-31
凯赛生物(688065)9月30日股东户数2.06万户,较上期增加7.55%
图解凯赛生物三季报:第三季度单季净利润同比增长8.60%
证券之星 · 10-31
图解凯赛生物三季报:第三季度单季净利润同比增长8.60%
凯赛生物(688065)披露2026年第三季度报告,10月30日股价下跌2.72%
证券之星 · 10-30
凯赛生物(688065)披露2026年第三季度报告,10月30日股价下跌2.72%
股市必读:10月28日凯赛生物现1笔折价20.66%的大宗交易 合计成交1200.01万元
证券之星 · 10-29
股市必读:10月28日凯赛生物现1笔折价20.66%的大宗交易 合计成交1200.01万元
10月27日凯赛生物现1笔折价16.85%的大宗交易 合计成交1200.03万元
证券之星 · 10-27
10月27日凯赛生物现1笔折价16.85%的大宗交易 合计成交1200.03万元
凯赛生物:生物法长链二元酸产品的毛利率主要受技术与工艺水平、原材料价格、产能利用率、产品市场价格等多重因素影响
证券之星 · 10-27
凯赛生物:生物法长链二元酸产品的毛利率主要受技术与工艺水平、原材料价格、产能利用率、产品市场价格等多重因素影响
凯赛生物:系列生物基聚酰胺销售额同比明显增长
证券之星 · 10-27
凯赛生物:系列生物基聚酰胺销售额同比明显增长
凯赛生物(688065)10月22日主力资金净卖出634.21万元
证券之星 · 10-23
凯赛生物(688065)10月22日主力资金净卖出634.21万元
股市必读:凯赛生物新发布《关于召开2026年第一次临时股东会的通知》
证券之星 · 10-22
股市必读:凯赛生物新发布《关于召开2026年第一次临时股东会的通知》
凯赛生物(688065)披露对外投资暨关联交易公告,10月21日股价下跌0.86%
证券之星 · 10-21
凯赛生物(688065)披露对外投资暨关联交易公告,10月21日股价下跌0.86%
股市必读:凯赛生物新发布《第三届董事会第十二次会议决议公告》
证券之星 · 09-28
股市必读:凯赛生物新发布《第三届董事会第十二次会议决议公告》
凯赛生物(688065)披露2025年员工持股计划预留份额分配公告,9月24日股价下跌2.49%
证券之星 · 09-24
凯赛生物(688065)披露2025年员工持股计划预留份额分配公告,9月24日股价下跌2.49%
加载更多
公司概况
公司名称:
上海凯赛生物技术股份有限公司
所属行业:
化学纤维制造业
上市日期:
2020-08-12
主营业务:
上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸(DC9-DC18)及其衍生产品、生物基戊二胺、系列生物基聚酰胺树脂及其改性产品、生物基连续纤维热塑型复合材料(Bio-PPACFRT)、生物基哌啶。
发行价格:
133.45
{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":34.72,"timestamp":1795158000000,"preClose":35.91,"halted":0,"volume":4383523,"delay":0,"changeRate":-0.0331,"floatShares":583000000,"shares":721000000,"eps":0.8832,"marketStatus":"已收盘","change":-1.19,"latestTime":"11-20 15:00:00","open":35.56,"high":35.86,"low":34.17,"amount":152000000,"amplitude":0.0471,"askPrice":34.72,"askSize":648,"bidPrice":34.71,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.8832,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":5,"adr":0,"adjPreClose":35.91,"symbolType":"stock_kcb","openAndCloseTimeList":[[1795138200000,1795145400000],[1795150800000,1795158000000]],"highLimit":39.5,"lowLimit":32.32,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":721289794,"isCdr":false,"pbRate":1.4,"roa":"--","peRate":39.311594,"roe":"2.95%","epsLYR":0.82,"committee":-0.768935,"marketValue":25043000000,"turnoverRate":0.0075,"status":1,"afterMarket":{"amount":0,"volume":0,"close":34.72,"buyVolume":0,"sellVolume":1550,"time":1795160037746,"indexStatus":"已收盘 11-20 15:30:00","preClose":35.91},"floatMarketCap":20255000000},"requestUrl":"/m/hq/s/688065","defaultTab":"news","newsList":[{"id":"2684185941","title":"凯赛生物(688065)11月19日主力资金净卖出400.54万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2684185941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684185941?lang=zh_cn&edition=full","pubTime":"2026-11-20 08:14","pubTimestamp":1795133686,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月19日收盘,凯赛生物报收于35.91元,上涨2.25%,换手率0.5%,成交量2.94万手,成交额1.05亿元。近5日资金流向一览见下表:凯赛生物融资融券信息显示,融资方面,当日融资买入620.2万元,融资偿还1109.57万元,融资净偿还489.38万元。凯赛生物主营业务:以合成生物学等学科为基础,利用生物制造技术,从事新型生物基材料的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026112000006402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684290978","title":"股市必读:凯赛生物新发布《关于2025年员工持股计划首次授予部分第一个锁定期业绩考核指标达成暨锁定期届满的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684290978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684290978?lang=zh_cn&edition=full","pubTime":"2026-11-20 02:34","pubTimestamp":1795113253,"startTime":"0","endTime":"0","summary":"截至2026年11月19日收盘,凯赛生物报收于35.91元,上涨2.25%,换手率0.5%,成交量2.94万手,成交额1.05亿元。公司公告汇总:凯赛生物2025年员工持股计划首次授予部分第一个锁定期届满,公司层面营业收入增长率31.57%,达成业绩考核目标,可解锁股票571,400股。交易信息汇总资金流向11月19日主力资金净流出400.54万元,占总成交额3.83%;游资资金净流出1074.72万元,占总成交额10.28%;散户资金净流入1475.26万元,占总成交额14.11%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026112000001223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684199417","title":"凯赛生物(688065)披露2025年员工持股计划首次授予部分第一个锁定期届满公告,11月18日股价下跌1.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2684199417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684199417?lang=zh_cn&edition=full","pubTime":"2026-11-18 22:26","pubTimestamp":1795011984,"startTime":"0","endTime":"0","summary":"截至2026年11月18日收盘,凯赛生物报收于35.12元,较前一交易日下跌1.76%,最新总市值为253.32亿元。该股当日开盘35.91元,最高36.19元,最低34.8元,成交额达8714.14万元,换手率为0.42%。公告显示,公司2025年员工持股计划首次授予部分第一个锁定期业绩考核指标已达成,锁定期届满。公司层面业绩考核目标完成,营业收入增长率为31.57%,达到解锁条件。可解锁股票数量为571,400股,占总股本比例0.08%。管理委员会将按规定出售股票并分配收益。后续将遵守相关交易限制规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111800043455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683541512","title":"凯赛生物(688065)11月12日主力资金净卖出534.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2683541512","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683541512?lang=zh_cn&edition=full","pubTime":"2026-11-13 08:31","pubTimestamp":1794529919,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月12日收盘,凯赛生物报收于37.73元,下跌3.53%,换手率0.62%,成交量3.61万手,成交额1.38亿元。近5日资金流向一览见下表:凯赛生物融资融券信息显示,融资方面,当日融资买入1636.55万元,融资偿还1146.87万元,融资净买入489.68万元。凯赛生物主营业务:以合成生物学等学科为基础,利用生物制造技术,从事新型生物基材料的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300009332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682418317","title":"股市必读:凯赛生物新发布《上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司2026年第一次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682418317","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682418317?lang=zh_cn&edition=full","pubTime":"2026-11-11 01:57","pubTimestamp":1794333470,"startTime":"0","endTime":"0","summary":"公司公告汇总:2026年第一次临时股东会审议通过《关于对外投资暨关联交易的议案》,关联股东回避表决,中小投资者单独计票。公司公告汇总上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司2026年第一次临时股东会的法律意见书上海市锦天城律师事务所就上海凯赛生物技术股份有限公司2026年第一次临时股东会出具法律意见书。上海市锦天城律师事务所对本次会议出具法律意见,认为会议召集、召开程序合法,表决结果有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100005032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682389275","title":"凯赛生物(688065)披露2026年第一次临时股东会决议公告,11月09日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682389275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682389275?lang=zh_cn&edition=full","pubTime":"2026-11-09 22:17","pubTimestamp":1794233823,"startTime":"0","endTime":"0","summary":"截至2026年11月9日收盘,凯赛生物报收于38.72元,较前一交易日下跌0.79%,最新总市值为279.28亿元。该股当日开盘39.14元,最高39.48元,最低38.55元,成交额达1.2亿元,换手率为0.53%。近日,凯赛生物发布《2026年第一次临时股东会决议公告》。公告显示,公司于2026年11月9日召开2026年第一次临时股东会,会议由董事长XIUCAI LIU(刘修才)主持,采用现场和通讯结合方式召开,出席会议的股东共147人,代表有表决权股份367,007,985股,占公司总股本的50.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900024006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680507430","title":"凯赛生物(688065)披露2025年员工持股计划预留授予部分非交易过户完成公告,11月04日股价上涨1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680507430","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680507430?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:41","pubTimestamp":1793803270,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘,凯赛生物报收于37.68元,较前一交易日上涨1.48%,最新总市值为271.78亿元。近日,上海凯赛生物技术股份有限公司披露《关于2025年员工持股计划预留授予部分非交易过户完成的公告》。公告显示,公司于2026年11月3日完成2025年员工持股计划预留授予部分的非交易过户,共15万股公司股票以25.08元/股的价格过户至员工持股计划账户,占总股本0.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400044227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680723602","title":"凯赛生物(688065)2026年三季报简析:营收净利润同比双双增长,公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2680723602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680723602?lang=zh_cn&edition=full","pubTime":"2026-11-01 06:24","pubTimestamp":1793485484,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期凯赛生物发布2026年三季报。截至本报告期末,公司营业总收入28.38亿元,同比上升11.51%,归母净利润5.27亿元,同比上升16.93%。按单季度数据看,第三季度营业总收入9.38亿元,同比上升7.26%,第三季度归母净利润1.54亿元,同比上升8.6%。本报告期凯赛生物公司应收账款体量较大,当期应收账款占最新年报归母净利润比达83.43%。答:2026年上半年,公司生物基聚酰胺系列实现营业收入1.08亿元,同比增长63%,毛利率0.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100001386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679272278","title":"凯赛生物(688065)9月30日股东户数2.06万户,较上期增加7.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679272278","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679272278?lang=zh_cn&edition=full","pubTime":"2026-10-31 17:17","pubTimestamp":1793438241,"startTime":"0","endTime":"0","summary":"证券之星消息,近日凯赛生物披露,截至2026年9月30日公司股东户数为2.06万户,较6月30日增加1444.0户,增幅为7.55%。在化学制品行业个股中,凯赛生物股东户数低于行业平均水平,截至9月30日,化学制品行业平均股东户数为3.09万户。从股价来看,2026年6月30日至2026年9月30日,凯赛生物区间跌幅为18.42%,在此期间股东户数增加1444.0户,增幅为7.55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100033295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679415522","title":"图解凯赛生物三季报:第三季度单季净利润同比增长8.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679415522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679415522?lang=zh_cn&edition=full","pubTime":"2026-10-31 01:21","pubTimestamp":1793380872,"startTime":"0","endTime":"0","summary":"证券之星消息,凯赛生物2026年三季报显示,前三季度公司主营收入28.38亿元,同比上升11.51%;归母净利润5.27亿元,同比上升16.93%;扣非净利润4.76亿元,同比上升11.13%;其中2026年第三季度,公司单季度主营收入9.38亿元,同比上升7.26%;单季度归母净利润1.54亿元,同比上升8.6%;单季度扣非净利润1.48亿元,同比上升11.7%;负债率11.64%,投资收益-1476.6万元,财务费用-91.21万元,毛利率34.69%。财报数据概要请见下图:本文数据来源于凯赛生物2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100003579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679243108","title":"凯赛生物(688065)披露2026年第三季度报告,10月30日股价下跌2.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679243108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679243108?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:59","pubTimestamp":1793372376,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘,凯赛生物报收于35.75元,较前一交易日下跌2.72%,最新总市值为257.86亿元。近日,上海凯赛生物技术股份有限公司披露2026年第三季度报告。报告显示,本报告期营业收入为937,724,498.63元,同比增长7.26%;归属于上市公司股东的净利润为154,225,167.44元,同比增长8.60%。年初至报告期末营业收入为2,837,905,343.41元,同比增长11.51%;归属于上市公司股东的净利润为526,955,811.70元,同比增长16.93%。研发投入合计为205,651,046.73元,同比增长15.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000058208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679822414","title":"股市必读:10月28日凯赛生物现1笔折价20.66%的大宗交易 合计成交1200.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679822414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679822414?lang=zh_cn&edition=full","pubTime":"2026-10-29 04:25","pubTimestamp":1793219133,"startTime":"0","endTime":"0","summary":"截至2026年10月28日收盘,凯赛生物报收于37.36元,上涨0.86%,换手率0.43%,成交量2.51万手,成交额9415.83万元。当日关注点交易信息汇总:10月28日主力资金净流出22.09万元,占总成交额0.23%; 交易信息汇总:当日发生1笔折价20.66%的大宗交易,合计成交1200.01万元。大宗交易10月28日凯赛生物发生1笔大宗交易,折价20.66%,成交金额1200.01万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900006570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678164179","title":"10月27日凯赛生物现1笔折价16.85%的大宗交易 合计成交1200.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678164179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678164179?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:08","pubTimestamp":1793099329,"startTime":"0","endTime":"0","summary":"证券之星消息,10月27日凯赛生物发生大宗交易,交易数据如下:大宗交易成交价格30.8元,相对当日收盘价折价16.85%,成交38.96万股,成交金额1200.03万元,买方营业部为长城证券股份有限公司重庆新南路证券营业部,卖方营业部为长城证券股份有限公司重庆新南路证券营业部。近三个月该股共发生4笔大宗交易,合计成交2.15万手,折价成交1笔。截至2026年10月27日收盘,凯赛生物报收于37.04元,下跌3.77%,换手率0.57%,成交量3.32万手,成交额1.26亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700036426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678125597","title":"凯赛生物:生物法长链二元酸产品的毛利率主要受技术与工艺水平、原材料价格、产能利用率、产品市场价格等多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2678125597","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678125597?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:33","pubTimestamp":1793086429,"startTime":"0","endTime":"0","summary":"证券之星消息,凯赛生物10月27日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700024249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678255711","title":"凯赛生物:系列生物基聚酰胺销售额同比明显增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2678255711","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678255711?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:33","pubTimestamp":1793086428,"startTime":"0","endTime":"0","summary":"证券之星消息,凯赛生物10月27日在投资者关系平台上答复投资者关心的问题。结合系列生物基聚酰胺及其复合材料产品的综合优势特点,公司正持续推进产品、客户开发,加大商业化推广力度,并通过技术迭代、工艺优化、规模化生产、产业链协同等多种方式推进降本增效工作。今年上半年,公司系列生物基聚酰胺销售额同比明显增长,长链聚酰胺实现规模化销售,毛利率亦呈现改善趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700024246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677918102","title":"凯赛生物(688065)10月22日主力资金净卖出634.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677918102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677918102?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:22","pubTimestamp":1792714944,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月22日收盘,凯赛生物报收于36.62元,下跌0.25%,换手率0.41%,成交量2.39万手,成交额8794.08万元。近5日资金流向一览见下表:凯赛生物融资融券信息显示,融资方面,当日融资买入537.48万元,融资偿还670.65万元,融资净偿还133.17万元。凯赛生物主营业务:以合成生物学等学科为基础,利用生物制造技术,从事新型生物基材料的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300007492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677609298","title":"股市必读:凯赛生物新发布《关于召开2026年第一次临时股东会的通知》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677609298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677609298?lang=zh_cn&edition=full","pubTime":"2026-10-22 02:47","pubTimestamp":1792608429,"startTime":"0","endTime":"0","summary":"公司公告汇总:公司将于2026年11月9日召开2026年第一次临时股东大会,审议《关于对外投资暨关联交易的议案》,股权登记日为2026年11月2日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200001663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677670482","title":"凯赛生物(688065)披露对外投资暨关联交易公告,10月21日股价下跌0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677670482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677670482?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:34","pubTimestamp":1792593260,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘,凯赛生物报收于36.71元,较前一交易日下跌0.86%,最新总市值为264.79亿元。该股当日开盘37.12元,最高37.3元,最低36.66元,成交额达6667.65万元,换手率为0.31%。近日,上海凯赛生物技术股份有限公司发布《关于对外投资暨关联交易的公告》。本次投资构成与关联方共同投资,尚需公司股东会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100041570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401147","title":"股市必读:凯赛生物新发布《第三届董事会第十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401147?lang=zh_cn&edition=full","pubTime":"2026-09-28 03:45","pubTimestamp":1790538314,"startTime":"0","endTime":"0","summary":"关于2025年员工持股计划预留份额分配的公告上海凯赛生物技术股份有限公司同意将15.00万股预留份额授予不超过54名激励对象,认购价格为25.08元/股;预留份额分配后,员工持股计划所持股票总数不超过公司股本总额的10%,单个持有人对应股票总数不超过公司股本总额的1%;标的股票自过户至员工持股计划名下之日起12个月后分两批解锁,每批解锁50%,解锁需满足公司、部门及个人层面业绩考核要求;该事项无需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469419","title":"凯赛生物(688065)披露2025年员工持股计划预留份额分配公告,9月24日股价下跌2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469419","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669469419?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:48","pubTimestamp":1790243336,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,凯赛生物报收于38.34元,较前一交易日下跌2.49%,最新总市值为276.54亿元。凯赛生物近日披露《关于2025年员工持股计划预留份额分配的公告》。公告显示,公司于2026年9月23日召开相关会议,审议通过《关于2025年员工持股计划预留份额分配的议案》,同意将15.00万股预留份额授予不超过54名激励对象,认购价格为25.08元/股。标的股票自过户至员工持股计划名下之日起12个月后分两批解锁,每批解锁50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400031254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795377205605,"stockEarnings":[{"period":"1week","weight":-0.0552},{"period":"1month","weight":-0.0542},{"period":"3month","weight":-0.233},{"period":"6month","weight":-0.193},{"period":"1year","weight":-0.2865},{"period":"ytd","weight":-0.2957}],"compareEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0483},{"period":"3month","weight":-0.0951},{"period":"6month","weight":-0.1408},{"period":"1year","weight":-0.1011},{"period":"ytd","weight":-0.1096}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","boardName":"化学纤维制造业","stockholders":"20567人(较上一季度增加7.55%)","perCapita":"28364股","listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","registeredCapital":"72128万元","survey":" 上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸(DC9-DC18)及其衍生产品、生物基戊二胺、系列生物基聚酰胺树脂及其改性产品、生物基连续纤维热塑型复合材料(Bio-PPACFRT)、生物基哌啶。","listedPrice":133.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}